CUE BIOPHARM.INC. DL-,001 WKN: A2JAT5 ISIN: US22978P1066 Kürzel: 1UC Forum: Aktien Thema: Hauptdiskussion

Pasha Sarraf, Director of Cue Biopharma Inc., has reported the acquisition of common shares of Cue Biopharma Inc. The full filing can be accessed through the link below.

Montag 1€🚀🚀🚀🚀🚀

🚀🚀🚀🚀🚀🚀

https://www.stocktitan.net/news/CUE/cue-biopharma-announces-pricing-of-12-0-million-public-sm20yqcgm77k.html

Well.... hat hier jemand ordentlich Gewinn gemacht oder wie siehts bei euch aus?^^

https://www.wallstreet-online.de/nachricht/18467796-cue-biopharma-appoints-industry-veteran-lucinda-warren-as-chief-business-officer

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-host-business-update-call-and-webcast-15

BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.

Sammaaaa! Was ist denn da los? Kennt da schon wer die Zahlen von morgen?

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-announces-strategic-prioritization-autoimmune

https://www.drugtargetreview.com/article/151759/translating-natures-cues-into-breakthrough-immunotherapies/

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-reports-fourth-quarter-and-full-year-2023

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional autoimmune pipeline developments and business updates.

Große Enttäuschung mit Hoffnung auf steilen Kursanstieg vor den Zahlen am 18.3.

Was für ein Tag gestern. Kommt vor. Hoffentlich heute die Erholung

Oh „Handelsrepublik“ wurde zensiert?;-)